Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMID 20093564)

Published in AJR Am J Roentgenol on February 01, 2010

Authors

Chaan S Ng1, David L Raunig, Edward F Jackson, Edward A Ashton, Frederick Kelcz, Kevin B Kim, Razelle Kurzrock, Teresa M McShane

Author Affiliations

1: Department of Radiology, University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA. cng@mdanderson.org

Articles citing this

Metabolic Heterogeneity in Human Lung Tumors. Cell (2016) 1.86

The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. Semin Oncol (2011) 1.07

Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol (2014) 0.93

CT perfusion of the liver: principles and applications in oncology. Radiology (2014) 0.92

DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88

Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. World J Radiol (2011) 0.87

DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol (2014) 0.85

DCE-MRI: a review and applications in veterinary oncology. Vet Comp Oncol (2011) 0.79

The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012. Mol Imaging Biol (2013) 0.78

Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: dynamic contrast-enhanced MR imaging. Magn Reson Med (2012) 0.77

Imaging in clinical trials. Cancer Imaging (2010) 0.76

Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterol (2013) 0.76

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev (2015) 0.75

Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. Sci Rep (2016) 0.75

Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Transl Oncol (2016) 0.75

Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography. World J Radiol (2012) 0.75

Articles by these authors

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77

Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19

Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14

Cancer: the road to Amiens. J Clin Oncol (2008) 3.10

Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86

Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83

Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77

NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69

Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol (2005) 2.36

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26

Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 2.19

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18

Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol (2012) 2.09

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04

Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02

Development of anatomically realistic numerical breast phantoms with accurate dielectric properties for modeling microwave interactions with the human breast. IEEE Trans Biomed Eng (2008) 2.01

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70

Sarcoidosis and malignancy. Clin Dermatol (2007) 1.67

Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources. Transl Oncol (2009) 1.66

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65

First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc (2003) 1.59

Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol (2011) 1.58

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58

The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol (2008) 1.57

Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma (2006) 1.55

Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55

Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol (2011) 1.54

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53

Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res (2007) 1.49

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48

Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res (2011) 1.46

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.43

Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer (2009) 1.42

Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model. Cancer Biol Ther (2009) 1.41

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res (2008) 1.41

Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist (2011) 1.40

BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma (2006) 1.40

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev (2012) 1.40

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer (2009) 1.39

Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer (2011) 1.37

Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood (2005) 1.34

A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One (2011) 1.34

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer (2010) 1.32

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer (2005) 1.31

Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book (2013) 1.30

PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget (2012) 1.30

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29

Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther (2007) 1.27

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res (2011) 1.26

Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther (2007) 1.26

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26

A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res (2010) 1.26

Patient, faculty, and self-assessment of radiology resident performance: a 360-degree method of measuring professionalism and interpersonal/communication skills. Acad Radiol (2004) 1.25

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24